Our Pricing

Mounjaro Single Pen - All Doses Available to Order

Published on: June 03, 2026

Searching for a mounjaro single pen uk online with flexible dosing options? Cured Pharmacy offers genuine UK-licensed Mounjaro KwikPens in all available dose strengths from £124.99, with transparent upfront pricing and a free consultation with our UK-registered prescribers. Every pen is dispensed following clinical assessment by our expert team, ensuring safe and personalised weight management support.

Understanding Mounjaro Single Pen Dosing

Mounjaro (tirzepatide) is supplied as pre-filled KwikPens, each containing a single weekly dose. The medication is available in six dose strengths: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg, allowing your UK prescriber to tailor treatment precisely to your clinical response and tolerance [1].

Clinical trials demonstrate that gradual dose escalation optimises both efficacy and tolerability. The SURPASS-1 trial showed that patients starting at 2.5mg and titrating upwards experienced fewer gastrointestinal side effects whilst achieving substantial weight reduction over 40 weeks [1]. At Cured Pharmacy, our prescribers follow MHRA-approved dosing schedules, typically starting patients at 2.5mg for four weeks before increasing to 5mg, with further adjustments based on individual progress.

Each Mounjaro pen is a single-use device designed for subcutaneous injection into the abdomen, thigh, or upper arm. The pen mechanism is engineered for ease of use, with a hidden needle and simple push-button administration that takes seconds to complete.

Why Choose Single Pen Ordering for Mounjaro

Ordering individual Mounjaro pens offers flexibility that multi-pen packs cannot match. Patients new to tirzepatide may prefer purchasing one pen at a time during the initial titration phase, allowing them to assess tolerability before committing to larger quantities. Similarly, those adjusting between dose strengths benefit from ordering precisely what their prescriber recommends without purchasing excess pens at lower or higher doses.

Single pen availability also supports patients managing treatment costs month by month. Whilst larger packs may offer marginal savings, the upfront cost can be prohibitive. At Cured Pharmacy, transparent pricing means you know exactly what you'll pay before completing your consultation, with no hidden fees or subscription obligations.

Our pharmacy maintains consistent stock across all Mounjaro dose strengths, ensuring you can access the specific pen your prescriber recommends without delays or forced substitutions.

Stock Availability Across All Doses

Supply chain challenges have affected weight loss medications across the UK, but Cured Pharmacy works directly with licensed wholesalers to maintain reliable stock of Mounjaro pens in every dose strength. Our team monitors availability daily and updates patients proactively if any temporary supply constraints arise, though our track record demonstrates consistent fulfilment rates exceeding industry standards.

How Mounjaro Compares to Other Weight Loss Treatments

Mounjaro's active ingredient, tirzepatide, is the first dual GIP/GLP-1 receptor agonist licensed for weight management in the UK. Unlike semaglutide-based treatments such as Wegovy, which activate only the GLP-1 pathway, tirzepatide stimulates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors [2].

This dual mechanism produced superior weight loss outcomes in head-to-head trials. The SURPASS-2 study compared tirzepatide directly against semaglutide 1mg in patients with type 2 diabetes, with tirzepatide 15mg achieving mean weight reduction of 11.2kg versus 5.7kg with semaglutide over 40 weeks [2]. Whilst these trials focused on diabetic populations, the SURMOUNT programme demonstrated similar advantages in non-diabetic adults seeking weight management [3].

Other injectable options available at Cured Pharmacy include Wegovy and Saxenda. Wegovy uses semaglutide, a proven GLP-1 agonist with robust clinical evidence from the STEP trials showing average weight loss of 15% over 68 weeks [4]. Saxenda contains liraglutide, an earlier-generation GLP-1 agonist requiring daily injection rather than weekly administration.

Choosing Between Injectable Options

Your UK prescriber will consider multiple factors when recommending between Mounjaro, Wegovy, and Saxenda. These include your baseline BMI, previous weight loss attempts, tolerance for injection frequency, budget considerations, and any contraindications in your medical history. Patients with significant weight to lose and no prior GLP-1 experience often start with lower-cost options before progressing to dual-agonist therapy if additional efficacy is needed.

Clinical Evidence Supporting Mounjaro for Weight Management

The SURMOUNT-1 trial enrolled 2,539 adults with obesity or overweight plus weight-related comorbidities, randomising participants to tirzepatide (5mg, 10mg, or 15mg) or placebo, all alongside lifestyle interventions. At 72 weeks, participants receiving tirzepatide 15mg achieved mean weight reduction of 22.5% from baseline, compared to 2.4% with placebo [3].

Importantly, 91% of participants on the highest dose achieved at least 5% weight loss—the threshold associated with meaningful health improvements—and 57% achieved at least 20% reduction [3]. These outcomes exceeded those seen in comparable semaglutide trials, positioning tirzepatide as the most effective pharmacological option currently licensed in the UK for chronic weight management.

Beyond weight reduction, tirzepatide demonstrated improvements in cardiometabolic markers including blood pressure, lipid profiles, and inflammatory markers. Participants reported enhanced physical functioning scores and quality of life measures, reinforcing that weight loss translates into tangible health benefits [1][3].

Starting Your Mounjaro Treatment at Cured Pharmacy

Beginning treatment requires a clinical consultation with one of our UK-registered prescribers. The online assessment takes under three minutes and covers your medical history, current medications, weight loss goals, and any contraindications. Our superintendent pharmacist, Tarun Kumar (GPhC 2233073), oversees all clinical decisions to ensure patient safety and regulatory compliance.

If Mounjaro is deemed appropriate, your prescriber will recommend a starting dose—typically 2.5mg for the first four weeks. You'll receive clear instructions on injection technique, storage requirements (refrigeration at 2-8°C until first use), and what to expect during the initial weeks. Common early side effects include mild nausea, reduced appetite, and occasional gastrointestinal discomfort, which typically diminish as your body adjusts [1].

Your prescription is fulfilled by our GPhC-registered pharmacy (9012511) using genuine UK-licensed Mounjaro pens sourced through authorised channels. We dispatch via tracked courier in discreet packaging, with most orders reaching patients within 24-48 hours. Follow-up consultations are available at no additional charge if you experience side effects or need dose adjustments.

Ongoing Monitoring and Dose Titration

Successful Mounjaro treatment involves gradual dose escalation every four weeks, subject to tolerability. Your prescriber will review your progress regularly, adjusting your dose to optimise weight loss whilst minimising side effects. Most patients reach their maintenance dose within 16-20 weeks, continuing at that level for sustained weight management. Our clinical team remains available throughout your treatment journey to address concerns and modify your regimen as needed.

Mounjaro Single Pen UK Online: Pricing and Value

At Cured Pharmacy, Mounjaro single pens are priced from £124.99, representing competitive UK pricing with full transparency before you complete your consultation. Unlike some providers that obscure costs behind subscription models or reveal pricing only after lengthy assessments, we display exact prices upfront so you can make informed decisions.

The cost per pen reflects several factors: the sophisticated manufacturing process for dual-agonist biologics, UK import and licensing requirements, pharmacy dispensing fees, and prescriber consultation costs. Whilst weight loss medications represent a financial commitment, clinical evidence demonstrates that effective treatment reduces long-term healthcare costs associated with obesity-related conditions including type 2 diabetes, cardiovascular disease, and joint problems.

We guarantee the lowest prices in the UK for genuine, licensed medications. Our pharmacy operates on transparent margins without the markup structures typical of high-street chains or venture-backed telehealth platforms. Every penny you pay goes toward authentic medication, expert clinical oversight, and reliable service—never inflated branding or investor returns.

Scientific References

1. Rosenstock, J., Wysham, C., Frías, J. P., et al. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet, 398(10295), 143-155. https://doi.org/10.1016/S0140-6736(21)01324-6 [accessed 13 August 2026]
2. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, phase 3 trial. The Lancet, 398(10308), 1301-1312. https://doi.org/10.1016/S0140-6736(21)02019-3 [accessed 13 August 2026]
3. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-218. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
4. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals and depend on multiple factors including diet, exercise, and adherence to treatment. Mounjaro is a prescription-only medicine and must be used under medical supervision.